Author Topic: Two new studies of progressive MS announced, as well as new Ocrevus data on long-term disability  (Read 83 times)

0 Members and 0 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 8523
  • MS diagnosed 1980
  • Location: Pacific Northwest

From Business Wire, June 14, 2018, an article based on an announcement from Genentech, "Genentech Announces New Ocrevus Data on Long-Term Disability Benefits in Primary Progressive Multiple Sclerosis and Initiation of Two Global Studies in Progressive MS":

The second new study mentioned in the article might be of interest for anyone with SPMS:

The second study, named CONSONANCE, will evaluate the efficacy of OCREVUS in the complete spectrum of progressive MS (PPMS and secondary progressive MS (SPMS)). The CONSONANCE study will measure the long-term effectiveness of OCREVUS in progressive MS with novel composite disability endpoints, including No Evidence of Progression (NEP) and No Evidence of Progression or Active Disease (NEPAD), in addition to a wide range of patient-relevant measures and advanced MRI outcomes. The four-year, Phase IIIb study is currently enrolling 600 people with PPMS or SPMS (in a 1:1 ratio) from across 26 countries. The study will also explore whether technology-enabled, continuous sensor-based and self-administered measures may detect changes in disability progression earlier than conventional clinical measures.
« Last Edit: June 14, 2018, 11:21:04 am by agate »
MS Speaks--online for 13 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010.


Related Topics

  Subject / Started by Replies Last post
0 Replies
Last post June 13, 2016, 08:20:12 am
by agate
0 Replies
Last post May 03, 2017, 10:06:55 am
by agate
2 Replies
Last post March 25, 2019, 07:26:33 am
by agate
0 Replies
Last post June 08, 2019, 09:32:13 am
by agate
0 Replies
Last post April 19, 2020, 08:53:27 pm
by agate